-
Zelluna ASA – Grant of Share Options
-
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
-
Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement
-
Zelluna ASA: New share capital registered
-
Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities
-
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement
-
Zelluna ASA: Private Placement and Retail Offering successfully placed
-
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data
